[1]
|
A. O. Soubani, K. B. Miller and P. M. Hassoun, “Pulmonary Complications of Bone Marrow Transplantation,” Chest, Vol. 109, No. 4, 1996, pp. 1066-1077.
doi:10.1378/chest.109.4.1066
|
[2]
|
E. Sakaida, C. Nakaseko, A. Harima, A. Yokota, R. Cho, Y. Saito, et al., “Late-Onset Noninfectious Pulmonary Complications after Allogeneic Stem Cell Transplantation are Significantly Associated with Chronic Graft-versusHost Disease and with the Graft-versus-Leukemia Effect," Blood, Vol. 102, No. 12, 2003, pp. 4236-4242.
doi:10.1182/blood-2002-10-3289
|
[3]
|
A. Palmas, A. Tefferi, J. L. Myers, J. P. Scott, S. J. Swensen, M. G. Chen, et al., “Late-Onset Noninfectious Pulmonary Complications after Allogeneic Bone Marrow Transplantation,” British Journal of Haematology, Vol. 100, No. 4, 1998, pp. 680-687.
doi:10.1046/j.1365-2141.1998.00617.x
|
[4]
|
F. Patriarca, C. Skert, A. Sperotto, D. Damiani, M. Cerno, A. Geromin, et al., “Incidence, Outcome, and Risk Factors of Late-Onset Noninfectious Pulmonary Complications after Unrelated Donor Stem Cell Transplantation,” Bone Marrow Transplant, Vol. 33, No. 7, 2004, pp. 751-758. doi:10.1038/sj.bmt.1704426
|
[5]
|
E. M. Gore, C. A. Lawton, R. C. Ash and R. J. Lipchik, “Pulmonary Function Changes in Long-Term Survivors of Bone Marrow Transplantation,” International Journal of Radiation Oncology, Biology, Physics, Vol. 36, No. 1, 1996, pp. 67-75. doi:10.1016/S0360-3016(96)00123-X
|
[6]
|
P. Fulgoni, M. C. Zoia, A. Corsico, M. Beccaria, G. Georgiani, G. Bossi, et al., “Lung Function in Survivors of Childhood Acute Lymphoblastic Leukemia,” Chest, Vol. 116, No. 5, 1999, pp. 1163-1167.
doi:10.1378/chest.116.5.1163
|
[7]
|
T. K. Marras, C. K. Chan, J. H. Lipton, H. A. Messner, J. P. Szalai and A. Laupacis, “Long-Term Pulmonary Function Abnormalities and Survival after Allogeneic Marrow Transplantation,” Bone Marrow Transplant, Vol. 33, No. 5, 2004, pp. 509-517. doi:10.1038/sj.bmt.1704377
|
[8]
|
B. N. Savani, A. Montero, C. Wu, N. Nlonda, E. Read, C. Dunbar, et al., “Prediction and Prevention of TransplantRelated Mortality from Pulmonary Causes after Total Body Irradiation and Allogeneic Stem Cell Transplantation,” Biology of Blood and Marrow Transplantation, Vol. 11, No. 3, 2005, pp. 223-230.
doi:10.1016/j.bbmt.2004.12.328
|
[9]
|
B. N. Savani, A. Montero, R. Srinivasan, A. Singh, A. Shenoy, S. Mielke, et al., “Chronic GVHD and Pretransplantation Abnormalities in Pulmonary Function Are the Main Determinants Predicting Worsening Pulmonary Function in Long-Term Survivors after Stem Cell Transplantation,” Biology of Blood and Marrow Transplantation, Vol. 12, No. 12, 2006, pp. 1261-1269.
doi:10.1016/j.bbmt.2006.07.016
|
[10]
|
B. P. Soule, N. L. Simone, B. N. Savani, H. Ning, P. S. Albert, A. J. Barrett, et al., “Pulmonary Function Following Total Body Irradiation (with or without Lung Shielding) and Allogeneic Peripheral Blood Stem Cell Transplant,” Bone Marrow Transplant, Vol. 40, No. 6, 2007, pp. 573-578. doi:10.1038/sj.bmt.1705771
|
[11]
|
K. Fujimaki, J. Taguchi, H. Fujita, M. Hattori, E. Yamazaki, N. Takahashi, et al., “Thiotepa/Cyclophosphamide/ TBI as a Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome,” Bone Marrow Transplant, Vol. 33, No. 8, 2004, pp. 789-792. doi:10.1038/sj.bmt.1704451
|
[12]
|
A. H. Filipovich, D. Weisdorf, S. Pavletic, G. Socie, J. R. Wingard, S. J. Lee, et al., “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report,” Biology of Blood and Marrow Transplantation, Vol. 11, No. 12, 2005, pp. 945-956. doi:10.1016/j.bbmt.2005.09.004
|
[13]
|
D. Przepiorka, D. Weisdorf, P. Martin, H. G. Klingemann, P. Beatty, J. Hows, et al., “1994 Consensus Conference on Acute GVHD Grading,” Bone Marrow Transplant, Vol. 15, No. 6, 1995, pp. 825-828.
|
[14]
|
H. M. Shulman, K. M. Sullivan, P. L. Weiden, G. B. McDonald, G. E. Striker, G. E. Sale, et al., “Chronic Graftversus-Host Syndrome in Man. A Long-Term Clinicopathologic Study of 20 Seattle Patients,” The American Journal of Medicine, Vol. 69, No. 2, 1980, pp. 204-217.
doi:10.1016/0002-9343(80)90380-0
|
[15]
|
J. W. Chien, D. K. Madtes and J. G. Clark, “Pulmonary Function Testing Prior to Hematopoietic Stem Cell Transplantation,” Bone Marrow Transplant, Vol. 35, No. 5, 2005, pp. 429-435. doi:10.1038/sj.bmt.1704783
|
[16]
|
F. Patriarca, V. Poletti, U. Costabel, M. L. Battista, A. Sperotto, M. Medeot, et al., “Clinical Presentation, Outcome and Risk Factors of Late-Onset Non-Infectious Pulmonary Complications after Allogeneic Stem Cell Transplantation,” Current Stem Cell Research & Therapy, Vol. 4, No. 2, 2009, pp. 161-167.
doi:10.2174/157488809788167436
|
[17]
|
L. Bashoura, S. Gupta, A. Jain, D. R. Couriel, K. V. Komanduri, G. A. Eapen, et al., “Inhaled Corticosteroids Stabilize Constrictive Bronchiolitis after Hematopoietic Stem Cell Transplantation,” Bone Marrow Transplant, Vol. 41, No. 1, 2008, pp. 63-67. doi:10.1038/sj.bmt.1705877
|
[18]
|
N. Maimon, J. H. Lipton, C. K. Chan and T. K. Marras, “Macrolides in the Treatment of Bronchiolitis Obliterans in Allograft Recipients,” Bone Marrow Transplant, Vol. 44, No. 2, 2009, pp. 69-73. doi:10.1038/bmt.2009.106
|
[19]
|
R. Or, B. Gesundheit, I. Resnick, M. Bitan, A. Avraham, M. Avgil, et al., “Sparing Effect by Montelukast Treatment for Chronic Graft versus Host Disease: A Pilot Study,” Transplantation, Vol. 83, No. 5, 2007, pp. 577-581.
doi:10.1097/01.tp.0000255575.03795.df
|